Literature DB >> 6374452

Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow.

G L Phillips, R H Herzig, H M Lazarus, J W Fay, S N Wolff, W B Mill, H Lin, P R Thomas, G P Glasgow, D C Shina.   

Abstract

Twenty-seven patients with malignant lymphoma in whom primary chemotherapy had failed and the prognosis was poor were treated with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. The median time to recovery of more than 500 neutrophils per microliter and more than 10,000 platelets per microliter was 18 and 24 days, respectively. Complete remission was achieved in 15 patients (56 per cent), five of whom were in continuous remission at this writing 19 to 71 months after transplantation without further therapy and one of whom was alive in a subsequent remission at 20 months. Fifteen patients died of lymphoma, three of interstitial pneumonitis, two of sepsis, and one of congestive heart failure. This experience shows that intensive therapy and autologous-marrow transplantation can produce prolonged remissions in patients with malignant lymphoma in whom conventional chemotherapy has failed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6374452     DOI: 10.1056/NEJM198406143102403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

1.  High-dose etoposide: from phase I to a component of curative therapy.

Authors:  Steven N Wolff; John D Hainsworth; F Anthony Greco
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

2.  Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.

Authors:  C C Anderson; A H Goldstone; R L Souhami; D C Linch; P G Harper; K A McLennan; M Jones; S J Machin; A M Jelliffe; J C Cawley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Cancer chemotherapy: new strategies for success.

Authors:  N A Berger
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

4.  Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.

Authors:  M H Gaspard; D Maraninchi; A M Stoppa; J A Gastaut; G Michel; N Tubiana; D Blaise; G Novakovitch; J F Rossi; P J Weiller
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 5.  Monoclonal antibodies--therapeutic and diagnostic uses in malignancy.

Authors:  J N Lowder; R Levy
Journal:  West J Med       Date:  1985-12

6.  Incidence and outcome of overt gastrointestinal bleeding in patients undergoing bone marrow transplantation.

Authors:  S Kaur; G Cooper; S Fakult; H M Lazarus
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

Review 7.  The management of follicular lymphoma.

Authors:  A Z Rohatiner; T A Lister
Journal:  Drugs       Date:  1994       Impact factor: 9.546

8.  High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.

Authors:  T Philip; J Dumont; F Teillet; D Maraninchi; N C Gorin; M Kuentz; J L Harousseau; M Marty; R Pinkerton; P Herve
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

9.  Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.

Authors:  G H Jackson; A L Lennard; P R Taylor; P Carey; B Angus; H Lucraft; R G Evans; S J Proctor
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.